Myelodysplastic Syndromes
Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
Cecilia BrownMyelodysplastic Syndromes | September 14, 2023
The proof-of-concept study showed that noninvasive hemoglobin measurement is “feasible,” but there were several ...
Read More
Cecilia BrownMeeting News | September 14, 2023
One aim is to evaluate the efficacy of oral decitabine/cedazuridine and magrolimab in intermediate to HR MDS.
Chadi Nabhan, MD, MBA, FACPMyelodysplastic Syndromes | September 14, 2023
Joseph Khoury, MD; Sanam Loghavi, MD; and Chadi Nabhan, MD, MBA, FACP, discuss the MDS classification systems.
Chadi Nabhan, MD, MBA, FACPMeeting News | September 13, 2023
Dr. Garcia-Manero discusses key data from the phase III COMMANDS trial.
Rami Komrokji, MDVideo Insights | September 10, 2023
Dr. Komrokji speaks about what might follow the recent FDA approval of luspatercept for certain patients with MDS.
Cecilia BrownMeeting News | September 9, 2023
Researchers sought to differentiate the mechanism of action of luspatercept from epoetin alfa.
Advertisement
Robert Hasserjian, MDMeeting News | September 9, 2023
Dr. Hasserjian discusses a presentation about the classification system that he gave at the SOHO Annual Meeting.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | September 9, 2023
A research team sought in their study to determine if the IPSS-M could also apply to CMML.
Phillip Scheinberg, MDMyelodysplastic Syndromes | September 8, 2023
"There's been a lot of focus on classifications and mutations: they're coming with a lot of force," Dr. Scheinberg said.
Chadi Nabhan, MD, MBA, FACPMeeting News | September 8, 2023
Dr. Platzbecker joins Chadi Nabhan, MD, MBA, FACP, to discuss MDS at the Eleventh Annual Meeting of SOHO.
Guillermo Garcia-Manero, MDMeeting News | September 7, 2023
Guillermo Garcia-Manero, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss the COMMANDS trial at the SOHO Annual Meeting.
Blood Cancers Today Staff WritersMeeting News | September 6, 2023
Allogeneic HSCT can yield favorable outcomes in treating patients with therapy-related MDS.
Blood Cancers Today Staff WritersMeeting News | September 5, 2023
A presentation by Dr. Rami Komrokji at the Eleventh SOHO Annual Meeting gave additional insights into the COMMANDS trial.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | September 5, 2023
Luspatercept is highly effective in treating ESA-naïve patients with LR-MDS.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | September 1, 2023
Response rates were high, and OS was improved in patients receiving venetoclax, although not statistically significant.
Cecilia BrownMyelodysplastic Syndromes | August 29, 2023
The expanded indication to the frontline setting is based on interim results from the pivotal phase III COMMANDS trial.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | August 4, 2023
Guillermo Garcia-Manero, MD, the 2023 SOHO President-Elect, shares his hopes and goals for the coming years.
Cecilia BrownMyelodysplastic Syndromes | July 26, 2023
The study's authors found evidence showing that "heme might serve as a rheostat directing cells to live or die."
Cecilia BrownMyelodysplastic Syndromes | July 25, 2023
Gilead Sciences, Inc, the manufacturer of the drug, recommends discontinuing magrolimab treatment in patients with MDS.
Cecilia BrownMyelodysplastic Syndromes | July 24, 2023
The single-center phase I/II study evaluated the triplet combination after hypomethylating agent failure.
Advertisement
Advertisement
Editorial Board